воскресенье, 29 мая 2016 г.

PharMerica's (PMC) "Outperform" Rating Reaffirmed at Barrington Research

PharMerica's (PMC) "Outperform" Rating Reaffirmed at Barrington Research


's stock had its "outperform" rating restated by equities researchers at Barrington Research in a research note issued to investors on Tuesday. They presently have a $34.00 target price on the stock, up from their previous target price of $30.00.



from Biotech News